Financials

Financials — What the Numbers Say

Zydus Wellness is an Indian wellness FMCG company (₹15,976 Cr market cap) carrying two acquisitions — the 2019 Heinz India deal (Complan, Glucon-D, Nycil, Sugar Free, Nutralite) and the FY26 Comfort Click UK consolidation — both bought in cash with debt.Fact Reported FY26 consolidated revenue jumped 46% to ₹3,961 Cr, but that is acquisition arithmetic, not organic growth: FY26 operating margin slipped to 13% (vs 14% FY25), interest expense more than doubled to ₹98 Cr, net profit fell 43% to ₹197 Cr (vs ₹347 Cr FY25), and consolidated EPS halved to ₹6.20.Fact Borrowings exploded from ₹188 Cr (Mar 2025) to ₹3,042 Cr (Sep 2025) to fund the UK deal.Fact Return on capital is ~6% — roughly one-fifth the FMCG peer median (32%).Fact The TTM P/E is ~81×, in line with Nestle India at 81× but earned on a fraction of the quality.Fact The single metric to watch: cash flow from operations versus the new ₹3,042 Cr debt service — does the acquired business actually deleverage the balance sheet, or does goodwill silently impair?

Reading the KPIs. Revenue is now near ₹4,000 Cr but more than ₹1,200 Cr of the FY26 increase is the first-time consolidation of the UK acquisition.Fact Operating margin in the low-teens looks healthy for an Indian FMCG until you compare it to Emami (26%) or Nestle India (23%) — and the company is paying for it with leverage rather than earning it from operations.Fact ROCE has stayed stuck near 6% since 2019 because the asset base now carries ~₹4,600 Cr of legacy Heinz goodwill plus the new UK goodwill on top.AI The 81× TTM P/E prices this as if it were structurally Nestle-quality; the operating data argues otherwise.AI

---

1. Revenue, Margins, and Earnings Power

What the income statement does for an investor. Revenue tells you scale and direction. Margins tell you whether each rupee of sale is actually profitable after the cost of goods, brand-building, and overhead. The two together tell you whether the business is compounding or just spending more to stay in place.

Three eras tell three different stories.

• FY2014–FY2018 (the asset-light era): revenue compounded from ₹404 Cr to ₹513 Cr, operating margins held near 23%, and the company earned ₹100–137 Cr on a near-debt-free balance sheet.Fact This was the original "Sugar Free + Everyuth + Nutralite" Zydus Wellness — small, profitable, and cash-generative.Fact
• FY2019–FY2021 (the Heinz integration): revenue more than tripled overnight (₹513 Cr → ₹1,767 Cr) but operating margin collapsed from 24% to 18% and net income actually fell from ₹137 Cr to ₹119 Cr.Fact The company paid ₹4,595 Cr for Complan, Glucon-D, Nycil and Sugar Free — a debt-funded deal that flooded the balance sheet with goodwill and the income statement with interest cost (₹140 Cr in FY20).Fact
• FY2022–FY2025 (the digestion): revenue grew slowly from ₹2,009 Cr to ₹2,709 Cr (low-double-digit CAGR, mostly price-led after Complan reformulation), debt got paid down, interest expense fell back to ₹12 Cr, and net income recovered to ₹347 Cr by FY25.Fact Margins, though, never returned to 23% — they sit in the 13–18% band.Fact
• FY2026 (the second acquisition): consolidation of Naturell (Dec 2024, RiteBite Max Protein) and Comfort Click UK (FY26) drove revenue up 46% but compressed margin to 13% and dragged net profit down 43% to ₹197 Cr.Fact

The margin story is not flattering. Operating margin has structurally re-rated downward from a 23% standalone base to a 13–18% consolidated band.Fact Two forces explain it: (1) the legacy portfolio (Sugar Free, Glucon-D, Complan) operates in price-elastic mass-market FMCG where pricing power is real but not Nestle-grade, and (2) every acquisition since 2019 has come in at lower margin than the legacy business.AI Net margin fell from a steady 26% pre-2019 to single digits in FY26 because of interest cost and higher depreciation on acquired intangibles.Fact

Quarterly trajectory — the seasonality is severe

The quarters tell a hidden truth. Zydus Wellness earns almost all of its operating profit in the first two quarters of the calendar year (Q4 and Q1 of its March-ending fiscal year) — these capture the summer Glucon-D / Nycil season.Fact Q2 and Q3 of the fiscal year (the monsoon and winter months) routinely run at 3–7% operating margins.Fact This is not a problem in itself, but it means quarterly comparisons need to be year-on-year not sequential, and it means the company needs the summer to fund its annual marketing.AI

The 1Q26 print (Mar-2026, the first quarter with full Comfort Click consolidation) was strong — revenue ₹1,485 Cr, 18% OPM, ₹162 Cr net profit — but it has not yet been tested through the monsoon quarter, when the legacy business turns near break-even.Fact Watch 2Q26 closely.

---

2. Cash Flow and Earnings Quality

What free cash flow means. Free cash flow (FCF) is the cash a business produces after paying for the inventory, working capital, and capex required to keep operating. It is what is actually available to repay debt, pay dividends, or fund acquisitions. If reported net income is high but FCF is consistently lower, the "earnings" are partly an accounting story; if FCF tracks net income, earnings are real.

Earnings quality has improved — but FY23 was a warning. From FY20 to FY21 FCF actually exceeded net income (165% and 226% conversion) because working capital was a tailwind during the COVID supply shock and Complan reformulation.Fact FY22–FY23 were the digestion years: FCF conversion collapsed to 52% then 15% as the cash conversion cycle swung from negative (a supplier-funded business) to positive (a working-capital-hungry business).AI FY24 and FY25 normalized back to 82% and 91% — a respectable level, though still below the 100%+ that high-quality FMCG names print.Fact

The single biggest cash-flow watch-out is the cash conversion cycle:

This is the most important slide in the financials. The cash conversion cycle measures how many days of working capital the company has to fund out of its own pocket. A negative CCC means suppliers and customers are funding the business — a hallmark of a strong consumer franchise. Zydus Wellness ran at −82 to −227 days from FY14 through FY20.Fact Then it inverted: payable days fell from 662 (FY19) to 122 (FY25), debtor days rose from 6 (FY18) to 49 (FY25), and the cycle is now a positive 75 days.Fact The acquired Heinz brands sit in modern trade and e-commerce channels that demand longer credit and pay slower than the original Zydus distribution.AI The CCC inversion is what makes FY26 cash generation worth watching closely — adding the UK retail business on top will not help.AI

---

3. Balance Sheet and Financial Resilience

Why the balance sheet matters. A balance sheet tells you what the company owns, what it owes, and how much room it has to make a mistake. For a consumer business with ~6% ROCE and a P/E in the 80s, balance-sheet flexibility is what justifies the valuation premium — or removes it.

Note on FY2026: the latest reported balance sheet is the Sep-2025 interim. Borrowings ballooned from ₹188 Cr (Mar-2025) to ₹3,042 Cr (Sep-2025) — this is the debt raised to fund the Comfort Click UK acquisition.Fact Total assets jumped from ₹6,442 Cr to ₹9,882 Cr in six months; fixed assets (which under Ind-AS includes acquired goodwill and intangibles) jumped by ₹3,300 Cr.Fact The FY2026 audited annual balance sheet will be filed with the FY26 annual report later this year; structurally it will look similar.AI

Debt and interest coverage

The risk is leverage, not insolvency. Interest coverage of 5.2× in FY26 is well above any covenant level and far above stress — operating profit of ₹510 Cr comfortably covers ₹98 Cr of interest.Fact But that ratio has fallen from 31.7× (FY25) to 5.2× (FY26) in one year, which is the second-biggest leverage step-up in the company's history.AI The first was FY20 (the Heinz year), and it took five years to deleverage from ₹1,569 Cr to ₹188 Cr of borrowings.Fact The new ₹3,042 Cr is roughly twice as large.AI If the acquired UK business generates the expected ~₹250–300 Cr of incremental EBITDA, the deal pays for itself in 5–7 years.AI If it does not, the deleveraging window stretches into the next decade.AI

Working capital and liquidity

The working-capital trajectory is the quiet concern. Inventory days dropped from the FY19 spike but have settled around 150 — high for an FMCG and structurally above pre-Heinz levels (108).Fact The combination of higher inventory, higher debtors, and a much smaller payable cushion means roughly ₹600 Cr of working capital is now permanently tied up that used to be supplier-funded.AI

---

4. Returns, Reinvestment, and Capital Allocation

The reinvestment test. ROCE and ROE measure how much profit the company earns on the capital invested in the business. For a quality FMCG, 25–40% is achievable. Below 10% usually means either the business is structurally low-returning, or it overpaid for an acquisition and has not yet earned through the goodwill.

A 20-point ROCE haircut. The Heinz acquisition dropped the company's structural return on capital from the 22–35% band to 5–7%.Fact The asset base now includes roughly ₹4,600 Cr of legacy goodwill and intangibles that earn nothing on their own — they had to be paid for.AI Even in the strongest year since 2019, ROCE never crossed 7%.Fact With the new UK goodwill stacked on top, return on capital is unlikely to improve until either the acquired businesses generate enough incremental profit to lift the numerator, or management writes down the carrying value.AI

Capital allocation — what management does with the cash

Management is a serial acquirer, not a buyback-driven capital allocator. Dividends have been small and steady (₹30–40 Cr a year, 10–25% payout).Fact There have been no buybacks in the period reviewed.Fact Most discretionary cash has gone toward (1) debt repayment after the Heinz deal, (2) capex on the existing plant footprint, and (3) two new acquisitions — Naturell (Dec 2024, ₹390 Cr) and Comfort Click (FY26, ~₹3,000 Cr).Fact The capital-allocation philosophy is clear: build scale via M&A.AI The question is whether the returns justify the leverage.

Share count has been roughly stable since FY2021 (an FY19 equity raise to part-fund Heinz lifted equity capital from ₹39 Cr to ₹58 Cr face value; an FY21 rights issue took it to ₹64 Cr).Fact FY22-FY26 EPS reflects pure underlying earnings change, not dilution.AI The bad news: the FY26 EPS print of ₹6.20 is below the FY18 standalone level of ₹6.85 — seven years of acquisitions have not yet produced per-share earnings growth.Fact

---

5. Segment and Unit Economics

Zydus Wellness does not report a detailed segment break-up in the consolidated financial statements; the company runs a single "Wellness Products" segment under Ind-AS 108.Fact The internal portfolio split (Glucon-D, Sugar Free, Complan, Nycil, Everyuth, Nutralite, plus the new Comfort Click brands) is disclosed only in qualitative form in the annual report.Fact

The information that is available, gathered from prior management commentary and the brand portfolio, tells a clear story:

The portfolio carries the economics of a mass-market summer business. Glucon-D + Nycil together account for roughly a third of revenue and almost all of the H1 (Q4/Q1 of the fiscal year) operating profit.AI Sugar Free is the highest-margin franchise (category leadership at small absolute size).Fact Complan post-reformulation is in revival mode after a difficult FY20–FY22 period.Fact The Comfort Click addition is a different business model — direct-to-consumer wellness sales in the UK — and its margin and working-capital profile are not yet comparable to the domestic portfolio.Fact

Detailed segment financials are not available in the dataset; a reader who wants to underwrite Complan vs Glucon-D unit economics will need to triangulate from management commentary in concalls and annual reports.AI

---

6. Valuation and Market Expectations

What "expensive" means in this context. Valuation has to be set against earnings power, growth, capital intensity, and balance-sheet flexibility. A 25× P/E for a 35%-ROCE business that grows 12% organically is cheap. A 25× P/E for a 6%-ROCE business that grows 5% organically is expensive. The level matters less than the level relative to the business.

A wide multiple range over the cycle. ZYDUSWELL has traded between ~24× (FY20, before the Complan reformulation worked) and ~81× (FY26, on consolidation-suppressed earnings).Fact The current ~78× TTM and ~81× on the freshly-printed FY26 EPS sit at the top of the historical range.Fact The bull case for staying at this multiple has three pieces:

1. FY27 normalization: if Comfort Click delivers ₹250 Cr of incremental EBITDA and the legacy business compounds 10%, FY27 net profit could mean-revert toward ₹350–400 Cr, dropping the forward P/E into the 40× zone.AI
2. De-leveraging: if FCF generation covers debt service, the ₹3,042 Cr can fall to ₹2,000 Cr by FY28 — restoring balance-sheet optionality.AI
3. Parent group support: Cadila / Zydus Lifesciences owns 69.6% — the parent is unlikely to let the consumer arm distress.Fact

The bear case is simpler. At ROCE of 6% versus a peer median of 32%, this is a structurally low-return business pricing as if it were structurally high-return.Fact Mean-reversion of multiple (not of earnings) implies meaningful downside.AI

Simple bear / base / bull frame

Read the table this way. The base case assumes Comfort Click integrates roughly on plan and the multiple compresses to the long-run average of ~50× — net upside is in the high teens.AI The bear case assumes integration costs persist into FY27 and the multiple re-rates toward Emami's 23× as the market reprices for ROCE — downside of ~45%.AI The bull case requires both successful integration and a successful Complan revival, with the market giving the company Nestle-style multiples on the strength of acquired growth.AI

---

7. Peer Financial Comparison

The peer chart shows the central anomaly. Most FMCG peers cluster along a line: higher ROCE earns a higher P/E.Fact Nestle (85% ROCE / 81× P/E) and Marico (47% ROCE / 62× P/E) sit on that line.Fact Emami (32% ROCE / 23× P/E) sits below it — arguably the value entry.Fact Zydus Wellness sits in the top-left: ~6% ROCE and 78× P/E.Fact The closest peer by capital structure (Tata Consumer at 9% ROCE / 78× P/E with similar M&A-funded leverage) is the only peer trading on comparable economics — and Tata Consumer has 7× the market cap and a more diversified portfolio.Fact

The peer gap that matters. ZYDUSWELL trades at roughly the same multiple as Nestle India on a fraction of the underlying return profile.AI The premium is justified only if you believe ROCE is temporarily depressed by goodwill that the company will earn through. The evidence from seven post-Heinz years is mixed — ROCE has not moved off 5–7% despite consistent operational execution.Fact

---

8. What to Watch in the Financials

What the financials confirm. This is a brand-rich, distribution-heavy consumer business that converts a fair share of its earnings to cash, runs with manageable absolute leverage, and is firmly profitable on an operating basis.AI The legacy portfolio works.

What the financials contradict. The valuation. There is no read of FY26 numbers that supports an 80× P/E on its own merits.AI The market is pricing two acquisitions to integrate cleanly and a Complan revival to play out and margins to mean-revert upward — all simultaneously.AI The historical pattern post-Heinz is that margins did not mean-revert; they reset lower.Fact

The first financial metric to watch is consolidated operating cash flow for FY26. If the audited FY26 cash-flow statement (due in the annual report) shows CFO of ₹500 Cr or more — covering the new interest bill, capex, and leaving room to repay debt — the deleveraging thesis is intact and the multiple is defensible.AI If CFO comes in below ₹350 Cr, the company is funding its interest with its working-capital cushion and the bear case starts to crystallize.AI